South Korean biosimilars developer Celltrion late yesterday announced new post-hoc analyses of its pivotal LIBERTY studies ...

South Korea-based Celltrion today announced that the European Commission (EC) has granted marketing authorization for three ...

Celltrion Inc., a major South Korean biopharmaceutical firm, said Wednesday it will buy back 100 billion won (US$69 million) worth of its own stocks to boost its shareholder value. Celltrion will ...

Celltrion announces 100 billion won share buyback, starts market purchase tomorrow Celltrion to start market share buyback ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two ...

Celltrion’s two biosimilar treatments for treating osteoporosis and preventing bone metastasis complications in cancer ...

South Koreas K. Pharma and Bio prepare for U.S. 25% pharmaceutical tariff U.S. pharmaceutical tariffs trigger strategic ...

Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab biosimilar candidate (Stoboclo and Osenvelt) and its aflibercept biosimilar ...

Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a ...

In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro talks about how the recent NASDAQ ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt ® (CT ...